Treatment of neu-N transgenic mice with the semi-synthetic inhibitor of FASN activity C75 has been found to significantly delay mammary tumor development (i.e. solely 20% of the C75-treated transgenic mice developed mammary carcinoma by 220 days compared to 50% in the vehicle control animals) and complete prevention of the disease in some neu-N animals [58]. This evidence concerns the gene FASN and breast carcinoma.